By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Cellular Dynamics International today said that its agreement with Roche to substantiate CDI's platform for assessing the potential toxicity of drug candidates for heart disease has progressed to a standard supply agreement.

The two-year agreement, which took effect in March 2009, to substantiate CDI's iCell Cardiomyocytes as a predictive tool was completed early, and the platform will now be incorporated into Roche's drug development decision-making process, CDI said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.